Targeted therapy for patients with activating BRAF mutations has demonstrated the potential for personalized medicine in patients with metastatic melanoma. Initial study results were promising and dramatic.
David Howard
Advertisement
Articles by David Howard
Advertisement
Latest Updated Articles
What’s Next With Next-Generation BRAF Inhibitors?Published: April 15th 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
